News Releases

Date Title and Summary
Nov 08, 2022 Artivion to Participate in Upcoming Investor Conferences
ATLANTA , Nov. 8, 2022 /PRNewswire/ -- Artivion, Inc.   (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.     Artivion's management team will present at the upcoming Stifel 2022
Nov 03, 2022 Artivion Reports Third Quarter 2022 Financial Results
Third Quarter and Recent Business Highlights: Achieved revenue of $76.8 million in the third quarter of 2022 versus $72.2 million in the third quarter of 2021, an increase of 6% on a GAAP basis and 11% on a non-GAAP constant currency basis On-X revenues increased 17% on a GAAP basis and 19% on a
Oct 20, 2022 Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2022 Financial Results
ATLANTA , Oct. 20, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2022 financial results will be released on Thursday, November 3, 2022 after the market closes.
Sep 29, 2022 Elizabeth Hoff Joins Artivion Board of Directors
ATLANTA , Sept. 29, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the appointment of Elizabeth A. Hoff to its Board of Directors effective October 1, 2022 .     "We are excited to welcome Elizabeth to our
Sep 23, 2022 Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial
Study Was Evaluating the Use of Apixaban in Patients Treated with Mechanical Aortic Valves ATLANTA , Sept. 23, 2022 /PRNewswire/ ---   Artivion, Inc. (NYSE: AORT) , a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has stopped the PROACT Xa clinical
Sep 14, 2022 Artivion to Present at the Deutsche Bank 30th Annual Leveraged Finance Conference
ATLANTA , Sept. 14, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present at the upcoming Deutsche Bank 30 th Annual Leveraged Finance Conference on Wednesday, September 21, 2022 .
Sep 06, 2022 Artivion to Participate in Upcoming Investor Conferences
ATLANTA , Sept. 6, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.     Artivion's management team will present at the upcoming Morgan Stanley 20
Aug 24, 2022 Artivion to Present at the Gilmartin Group Emerging Growth Company Showcase
ATLANTA , Aug. 24, 2022 /PRNewswire/ --   Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present virtually at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase on Wednesday, August 31, 2022 .
Aug 04, 2022 Artivion Reports Second Quarter 2022 Financial Results
ATLANTA , Aug. 4, 2022 /PRNewswire/ --      Second Quarter and Recent Business Highlights: Achieved revenue of $80.3 million in the second quarter 2022 versus $76.1 million in the second quarter of 2021, an increase of 6% on a GAAP basis and 9% on a non-GAAP constant currency basis Enrolled first
Aug 03, 2022 Artivion to Participate in Upcoming Investor Conferences
ATLANTA , Aug. 3, 2022 /PRNewswire/ --  Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.     Artivion's management team will present at the upcoming Canaccord Genuity
Displaying 1 - 10 of 23